首页|地舒单抗对绝经后骨质疏松症患者糖脂及心血管指标的影响

地舒单抗对绝经后骨质疏松症患者糖脂及心血管指标的影响

扫码查看
目的 探讨地舒单抗对绝经后骨质疏松症(postmenopausal osteoporosis,POMP)患者糖脂代谢及心血管的影响.方法 选取 2017 年 1 月 1 日至 2022 年 8 月 31 日在新疆维吾尔自治区人民医院诊断为绝经后原发性骨质疏松症的患者,将患者按照使用药物的不同分为地舒单抗联合阿托伐他汀钙组(A组)、地舒单抗组(B 组)及对照组(C组),收集三组患者的一般资料、实验室检查,比较三组患者的基本信息、骨代谢、糖代谢、脂代谢及心肌损伤指标.结果 治疗 1 年后,三组患者的碱性磷酸酶水平较治疗前下降,差异有统计学意义(P<0.05);药物治疗后三组患者乳酸脱氢酶(lactate dehydrogenase,LDH)及空腹血糖水平比较,差异有统计学意义(P<0.05);与C组比较,治疗后B组空腹血糖降低更为显著,LDH升高更为显著(P<0.05).组内治疗前后C组血清肌酸激酶(creatine kinase,CK)水平比较、A组LDH水平比较,差异有统计学意义(P<0.05).结论 地舒单抗治疗对POMP患者糖代谢的影响可能是有益的,对于糖尿病合并骨质疏松的患者使用地舒单抗可能是更好的选择.本研究初步证明POMP患者地舒单抗联合他汀可使LDH水平降低,而仅使用阿托伐他汀钙治疗患者CK升高,表明地舒单抗可能在调节糖代谢、脂代谢及预防心血管事件方面更有优势.
Effect of denosumab on glycolipids and cardiovascular indices in patients with postmenopausal osteoporosis
Objective To investigate the effects of denosumab on glucose-lipid metabolism and cardiovascular in patients with postmenopausal osteoporosis(POMP).Methods Patients diagnosed with POMP in Xinjiang Uygur Autonomous Region People's Hospital from 1 January 2017 to 31 August 2022 were selected,and the patients were divided into the desutumomab and atorvastatin calcium group(group A),the desutumomab group(group B),and the control group(group C)according to the drugs used,and the general data and laboratory examinations of the patients in the three groups were collected.General information and laboratory tests were collected from the three groups of patients,and basic information,bone metabolism,glucose metabolism,lipid metabolism,and myocardial injury indexes were compared among the three groups of patients.Results After 1 year of treatment,the alkaline phosphatase level of the three groups of patients decreased significantly compared with that before treatment(P<0.05),and the differences in lactate dehydrogenase(LDH)and fasting blood glucose levels of the three groups of patients after drug treatment were statistically significant(P<0.05),and compared with group C,the reduction of fasting blood glucose in group B was more significant,and the increase in LDH was more significant(P<0.05)after treatment.Comparison of creatine kinase(CK)level in group C and LDH level in group A before and after treatment within the group,the difference was statistically significant(P<0.05).Conclusion The effect of denosumab treatment on glucose metabolism in patients with POMP may be beneficial,and the use of denosumab may be a better choice for patients with diabetes combined with osteoporosis.The present study provides preliminary evidence that denosumab in combination with statin in patients with POMP resulted in lower LDH levels,whereas CK was elevated in patients treated with atorvastatin only,suggesting that denosumab may be more advantageous in regulating glucose metabolism,lipid metabolism,and the prevention of cardiovascular events.

DenosumabOsteoporosisGlucose metabolismLipid metabolismCardiovascular disease

王卢凤、张凯迪、郭艳英

展开 >

石河子大学医学院,新疆石河子 832000

新疆维吾尔自治区人民医院内分泌与代谢病科 新疆糖尿病临床医学研究中心,新疆乌鲁木齐 830000

地舒单抗 骨质疏松 糖代谢 脂代谢 心血管疾病

新疆维吾尔自治区科技厅平台建设项目

PT1601

2024

中国现代医生
中国医学科学院

中国现代医生

影响因子:1.571
ISSN:1673-9701
年,卷(期):2024.62(14)
  • 18